Menu
← Oncology Approval Tracker
FDA DECISION ·
Lymphir
denileukin diftitox-cxdl · Citius Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic treatment.
LAMPGEN ANALYSIS
Why it matters
This IL-2 receptor-directed fusion protein adds an option in previously treated cutaneous T-cell lymphoma.
What research teams should watch
Set up skin disease scoring and watch for capillary leak with serial weight, vital signs and albumin review.
PRIMARY RECORDS